Fisher to sell Cholestech LDX System in US:
This article was originally published in Clinica
Executive Summary
Fisher HealthCare is to distribute Cholestech's LDX System in the US under a multi-year, non-exclusive agreement. Haywood, California-based Cholestech's product, which aids in the detection of cardiovascular disease, is a telephone-sized device that carries out multiple, simultaneous tests from a drop of blood, providing results in under five minutes. The company claims results are as accurate as similar tests conducted in clinical and hospital labs. Fisher HealthCare, a division of Fisher Scientific, plans to distribute the product to over 75,000 acute care and physician office laboratories.
You may also be interested in...
Lilly Can Rest Easy As Tirzepatide Scores Phase III Sleep Apnea Win
Topline results from two studies in obstructive sleep apnea among obese adults showed efficacy crossing the 50% threshold that physicians have called clinically meaningful.
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.